With a market capitalization (market cap) of $1.81B — a measure of how much the company is worth — Hemab Therapeutics Holdings, Inc. Common Stock ranks #2,040 among the 2,444 companies tracked, and 268th in Healthcare as of November 11, 2026. Shares trade at $38.77, down 9.44% on the day.
As of November 11, 2026 · Prices may be delayed
of 2,444 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Listed less than one year ago
Listed less than one year ago
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 6, 2026. The headline market cap is from the ranking update on November 11, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 6, 2026 | $1.48B | — | $49.02 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.81B as of November 11, 2026.
Market cap = share price × shares outstanding.
Hemab Therapeutics Holdings, Inc. Common Stock's ranking market cap is the reported market cap from the latest ranking update, with a share price of $37.95 as of November 11, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.48B on November 6, 2026. See how the ranking works.
The ranking snapshot ($1.81B as of November 11, 2026) is FMP company-screener market cap. The historical observation ($1.48B on November 6, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 27,442,910 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.04B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $37.95. The headline price of $38.77 is from the ranking update on Nov 11, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.35T | +1.44% |
| #19 | Johnson & Johnson JNJ | $675.92B | -0.47% |
| #23 |
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 11, 2026, Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is worth $1.81B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Hemab Therapeutics Holdings, Inc. Common Stock’s book equity is about −$176.64M. Market cap is the market value of the outstanding shares. As of November 11, 2026, its market cap is $1.81B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Hemab Therapeutics Holdings, Inc. Common Stock ranks #2,040 among the 2,444 companies tracked on MarketCapLens. In Healthcare it ranks #268 of 357.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
Listed this year; no prior year-end value to compare
Listed less than five years ago
Undefined when revenue is zero
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $519.48B |
| +0.20% |
| #30 | Merck & Co., Inc. MRK | $364.98B | -0.48% |
| #31 | UnitedHealth Group Incorporated UNH | $363B | +1.89% |
| #37 | Novartis AG NVS | $308.34B | -0.26% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2037 | The Andersons, Inc. ANDE | $1.83B | -1.27% |
| #2038 | Nayax Ltd. NYAX | $1.82B | +0.28% |
| #2039 | S&T Bancorp, Inc. STBA | $1.81B | +0.06% |
| #2041 | Newmark Group, Inc. NMRK | $1.81B | -6.21% |
| #2042 | Pony AI Inc. American Depositary Shares PONY | $1.81B | -5.15% |
| #2043 | LeMaitre Vascular, Inc. LMAT | $1.81B | -2.64% |
Hemab Therapeutics Holdings, Inc. Common Stock’s ranking market cap of $1.81B comes from the same snapshot as the rest of this site, as of November 11, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 27,442,910. The ranking snapshot ($1.81B as of November 11, 2026) is FMP company-screener market cap. The historical observation ($1.48B on November 6, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) shares trade at $38.77, down 9.44% on the day, as of November 11, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.